SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

MRK is experiencing heightened trading activity as the market evaluates its evolving cancer drug portfolio, particularly in the wake of positive late-stage trial results for its combination therapies. Investors are closely monitoring the company's long-term strategy to address the impending patent cliff for its top-selling drug Keytruda, while also scrutinizing potential M&A moves in the oncology sector.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point of community debate as investors weigh the project's long-term utility in quantum-resistant blockchain infrastructure against its extended period of price stagnation. While some traders are actively accumulating positions in anticipation of a potential market rotation and upcoming adoption catalysts, others remain deeply skeptical, citing ongoing price dilution and a lack of sustained bullish momentum.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is facing intense volatility and market skepticism as investors grapple with the discovery of a critical vulnerability in its privacy protocol that theoretically allowed for unauthorized token generation. While the development team has issued a patch, the community remains divided and fearful, with many debating the coin's long-term supply integrity and the broader implications for privacy-focused projects.

Lighter is a decentralized trading platform built for unmatched security and scale. It’s the first exchange to offer verifiable order matching and liquidations while delivering best-in-class performance on par with traditional exchanges.

lighter

Lighter is capturing significant market attention following the implementation of a programmatic token burn and a revenue-funded buyback program, which has drawn comparisons to other high-growth decentralized derivatives exchanges. The community is actively discussing the platform's expanding perpetual futures volume and its strategic integration with the Robinhood ecosystem as key drivers of institutional and retail interest.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil (SCO) is facing intense community debate as traders grapple with its complex structure and decay issues while reacting to headlines regarding potential peace deals and supply fluctuations in the Strait of Hormuz. Investors are actively discussing the impact of a looming reverse split, with sentiment sharply divided between those betting on an oil price collapse to trigger a recovery and others viewing the ETF as a trap due to its volatility and tracking mechanics.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is seeing heightened investor activity driven by speculation over a potential buyout or strategic shift, coupled with optimism surrounding its flagship cancer therapy and pipeline potential. The community is actively debating the company's valuation, questioning management's execution against a backdrop of significant institutional interest and long-term upside targets.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is experiencing significant market volatility and high trading volume following its fourth-quarter earnings release, where investors are weighing a top-and-bottom-line miss against strong order growth and positive forward-looking guidance. While some community members highlight concerns over high valuations and competitive pressure from AI-driven automation, bulls are pointing to the company's aggressive global expansion and improving unit economics as catalysts for a potential rebound.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is drawing significant investor focus due to active speculation surrounding a potential buyout, fueled by the company's first-mover status in the MASH market and its expanding, robust pipeline. While community discussion remains polarized between those banking on acquisition by major pharma players and those questioning the management's capital allocation and lack of immediate profitability, strong institutional interest and recurring rumors continue to drive high volatility and active trading interest in the stock.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token is gaining significant community attention as investors rally around its aggressive token burn strategy, which is rapidly reducing supply and pushing the project toward deflationary territory. The project is trending due to strong demand for its private AI services, fueling optimism about future utility and potential price appreciation as it carves out a niche in the competitive AI sector.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is currently experiencing significant momentum and institutional accumulation, fueled by anticipation surrounding their NXC-201 CAR-T therapy for AL amyloidosis. The community is actively tracking the company's regulatory milestones, including breakthrough therapy designations and pivotal trial progress, while discussing the potential for a high-value M&A outcome as the therapy nears commercial readiness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline...

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new...

Savara Announces Chief Financial and Administrative Officer Transition

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of...

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on...

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the...

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reports long-term efficacy and safety data...

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise...

Savara Reports First Quarter Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2026 and...

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a...

Savara (SVRA) to Release Earnings on Tuesday

Savara (NASDAQ:SVRA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.14	--	--	N/A
Q1 '26	-$0.14	-$0.15	-11.11%	MISSED
Q4 '25	-$0.12	-$0.13	-10.64%	MISSED
Q3 '25	-$0.13	-$0.14	-5.66%	MISSED
Q2 '25	-$0.12	-$0.14	-16.67%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

SVRASavara Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest SVRA News